Navigation Links
BioMarin Announces First Quarter 2011 Financial Results
Date:4/28/2011

candidates; the continued clinical development and commercialization of Aldurazyme, Naglazyme, Kuvan, Firdapse, and its product candidates; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme, Kuvan, and Firdapse; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials, particularly with respect to GALNS, Firdapse, PEG-PAL, BMN 673 and BMN 701; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme, Kuvan and Firdapse; actual sales of Aldurazyme, Naglazyme Kuvan and Firdapse; Merck Serono's activities related to Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2009 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... with AbbVie (NYSE: ABBV ) to develop and ... ENHANZE ™ platform. Under ... an initial $23 million payment, followed by milestone ... up to nine collaboration targets. These payments are ...
(Date:6/3/2015)... Calif. , June 3, 2015  Flow ... sector around the globe and keeping track of ... this competitive market. In particular, ensuring user-friendliness, fluorescence ... sensitivity are the most important factors influencing end-user ... consumer base. New analysis from Frost ...
(Date:6/3/2015)... , June 3, 2015  (AHIP Institute Booth ... information network, will be providing a wide range of ... future during the America,s Health Insurance Plan,s (AHIP,s) ... Tenn. Availity released a ... problem of waste and missed opportunities." The report ...
Breaking Medicine Technology:Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 2Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 3Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 4Availity to Share Insights, Tools and Strategies at AHIP 2015 to Enable Health Plans to Achieve Long-term, Sustainable Success in an Evolving Value-based Environment 2Availity to Share Insights, Tools and Strategies at AHIP 2015 to Enable Health Plans to Achieve Long-term, Sustainable Success in an Evolving Value-based Environment 3
... premier Canadian pharmacy intermediary since 2002, reveals the top ... a Canada pharmacy . 1. Low Prices - ... less than the U.S. price and SaveRxCanada.com has been negotiating the ... – Many patients are elderly and find it difficult to get ...
... 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: ... medical dressings, medical disposables and non-woven fabric made from ... it will release financial results for its second quarter ... Medical,s senior management will host a conference call to ...
Cached Medicine Technology:Canadian Pharmacy Intermediary's Top Reasons U.S. Customers Choose Canada Online Pharmacies Revealed by SaveRxCanada.com 2Winner Medical Group Inc. to Host Second Quarter 2011 Earning Conference Call on Wednesday, May 11, 2011 at 08:30 a.m. EDT 2
(Date:6/3/2015)... The Bay Pines VA Healthcare System (VAHCS) will ... Administration’s (VHA) National Women Veterans Campaign on June 12. The ... on the first floor of the C.W. Bill Young VA ... Veterans and their families, Veteran Service Organizations, other stakeholders, and ... printable event flyer, click here. , The event will showcase ...
(Date:6/3/2015)... 03, 2015 Hexagon Geospatial is pleased ... of its 2015 U.S. Education Challenge, which showcases the ... college or university in the U.S. , This ... on Remote Sensing and Civil Engineering at the University ... Surface Cracks Detection and Assessment Based on Hyper-spatial Resolution ...
(Date:6/3/2015)... Johnson & Johnson and its Janssen Pharmaceuticals ... a Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) filed by the ... to market the antipsychotic drug. Court records filed ... Attorney General moved to dismiss the case on May ... amounts to just a fraction of the $1.2 billion ...
(Date:6/3/2015)... WA (PRWEB) June 03, 2015 On June ... the majority of genetic drug sensitivity (pharmacogenetic) testing that it ... to impact as many as 19 million of the 49 ... risk of costly and life-threatening adverse drug events.(1) Sadly, if ... Medicare millions. , Precision Medicine, the use of an individual’s ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Array ... exchange technology, has announced that CEO Jonathan Rickert will ... 2015 on June 4, 2015. The session will ... technologies are disrupting traditional business models in health care, ... value. , WHAT: Digital Transformation and the Health ...
Breaking Medicine News(10 mins):Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 2Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 3Health News:Hexagon Geospatial Announces U.S. Education Challenge Winner at HxGN Live 2015 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2
... Rochelle, NY, December 11, 2007A prestigious group of physicians, ... VA on March 28-30, 2008 at the Williamsburg Lodge ... novel diagnostic procedures, and innovative research advances that impact ... is available at www.bioconferences.com/wh, ...
... outcomes , TUESDAY, Dec. 11 (HealthDay News) -- ... as effective as standard cardiopulmonary resuscitation (chest compressions ... of people who,ve suffered cardiac arrest. , That,s ... Dec. 11 issue of the journal Circulation ...
... study found , , TUESDAY, Dec. 11 (HealthDay News) -- ... interpretations of diagnostic mammograms, a new study found. , ... much as they were due to differences in the ... the study, published in the Dec. 11 issue of ...
... system may be needed, experts say , , TUESDAY, Dec. ... improve medical care for low-income seniors produced mixed results, ... outcomes indicates the need for a new analysis of ... experts said. , "We were able to stabilize medical ...
... Messages - Good News on,Youngest Teens, While Older Teens, ... New data announced in,today,s Monitoring the Future study shows ... that the declines for 10th graders,are statistically insignificant and ... fourth consecutive year, the rates for 10th and 12th ...
... the,fastest-growing Hispanic television network in the United States, is ... Director Nora Volkow,on this Monday,s broadcast of "Issues: Caras ... Armando Guzman., Dr. Volkow, who has been the ... drug addiction is a disease of the human brain. ...
Cached Medicine News:Health News:Chest Compressions Effective in Emergency Cardiac Arrest 2Health News:Diagnostic Mammogram Readings Vary by Radiologist 2Health News:Diagnostic Mammogram Readings Vary by Radiologist 3Health News:Home-Based Senior Care Program Has Limited Benefits 2Health News:Statement by the American Legacy Foundation(R) on Youth Smoking Rates 2Health News:Statement by the American Legacy Foundation(R) on Youth Smoking Rates 3Health News:Statement by the American Legacy Foundation(R) on Youth Smoking Rates 4Health News:National Institute on Drug Abuse Director Nora Volkow Speaks about the Dangers of Narcotics on Azteca America's Political Forum 'Issues: Caras y Voces' 2Health News:National Institute on Drug Abuse Director Nora Volkow Speaks about the Dangers of Narcotics on Azteca America's Political Forum 'Issues: Caras y Voces' 3
... Constructed of optical steel ... electro-plate. Comes with custom ... that create a seal ... for increased scatter radiation ...
... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
... eye protection Properly manufactured radiation protective ... radiation. Our high quality frames and materials ... minimized weight. Our lenses are made of ... all industry standards. Most Pulse Glasses are ...
... Both lenses and frames are designed with the ... Our lenses are Schott RS-520 (also called SF-6) ... glass. These lenses meet standards, as set for ... correction. ,While our eyewear is protecting your ...
Medicine Products: